Pasithea Therapeutics shares were up 67% to $3.46 in premarket trading after the company said that an external safety review committee recommended that its Phase 1 clinical trial of PAS-004 in ...

Pasithea Therapeutics Corp. is a biotechnology company focuses on the research and discovery of new and treatments for psychiatric and neurological disorders. The company was founded by Yassine ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...